4-{(S)-4-tert-butoxycarbonyl-2-[(6-phenyl-pyridine-2-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester | 1019926-30-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-{(S)-4-tert-butoxycarbonyl-2-[(6-phenyl-pyridine-2-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester
• 英文别名: ethyl 4-[(2S)-5-[(2-methylpropan-2-yl)oxy]-5-oxo-2-[(6-phenylpyridine-2-carbonyl)amino]pentanoyl]piperazine-1-carboxylate
• CAS: 1019926-30-7
• 化学式: C₂₈H₃₆N₄O₆
• 分子量: 524.617
• InChiKey: MTJZTLSBLLHONU-QHCPKHFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  38
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  118
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-{(S)-4-tert-butoxycarbonyl-2-[(6-phenyl-pyridine-2-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 (4S)-5-[4-(ethoxycarbonyl)piperazin-1-yl]-5-oxo-4-([(6-phenylpyridin-2-yl)carbonyl]amino)pentanoicacid
  参考文献：
  名称：

  Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation

  摘要：

  Polymer-assisted solution-phase (PASP) parallel library synthesis was used to discover a piperazinyl-glutamate-pyridine as a P2Y(12) antagonist. Exploitation of this lead provided compounds with excellent inhibition of platelet aggregation as measured in a human platelet rich plasma (PRP) assay. Pharmacokinetic and physiochemical properties were optimized leading to compound (4S)-4-[({4-[4-(methoxymethyl)piperidin-1-yl]-6-phenylpyridin-2-yl} carbonyl)amino]-5-oxo-5-{4-[(pentyloxy) carbonyl]piperazin-1-yl}pentanoic acid 22J with good human PRP potency, selectivity, in vivo efficacy and oral bioavailability. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.06.075
• 作为产物：
  描述：

  tert-butyl (4S)-5-oxo-4-([(6-phenylpyridin-2-yl)carbonyl]amino)-5-piperazin-1-ylpentanoate 、 氯甲酸乙酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 4-{(S)-4-tert-butoxycarbonyl-2-[(6-phenyl-pyridine-2-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester
  参考文献：
  名称：

  Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation

  摘要：

  Polymer-assisted solution-phase (PASP) parallel library synthesis was used to discover a piperazinyl-glutamate-pyridine as a P2Y(12) antagonist. Exploitation of this lead provided compounds with excellent inhibition of platelet aggregation as measured in a human platelet rich plasma (PRP) assay. Pharmacokinetic and physiochemical properties were optimized leading to compound (4S)-4-[({4-[4-(methoxymethyl)piperidin-1-yl]-6-phenylpyridin-2-yl} carbonyl)amino]-5-oxo-5-{4-[(pentyloxy) carbonyl]piperazin-1-yl}pentanoic acid 22J with good human PRP potency, selectivity, in vivo efficacy and oral bioavailability. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.06.075

文献信息

• 2-AMINOCARBONYL-PYRIDINE DERIVATIVES
  申请人：Caroff Eva

  公开号：US20100035895A1

  公开（公告）日：2010-02-11

  The present invention relates to 2-aminocarbonyl-pyridine derivatives of Formula (I) and their use as P2Y 12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis.

  本发明涉及公式（I）的2-氨基羰基吡啶衍生物及其在治疗和/或预防与血小板聚集相关的周围血管、内脏、肝脏和肾脏血管、心血管和脑血管疾病或病况中作为P2Y12受体拮抗剂的用途，包括血栓形成。
• Piperazinyl Glutamate Pyridines as Potent Orally Bioavailable P2Y₁₂ Antagonists for Inhibition of Platelet Aggregation
  作者：John J. Parlow、Mary W. Burney、Brenda L. Case、Thomas J. Girard、Kerri A. Hall、Peter K. Harris、Ronald R. Hiebsch、Rita M. Huff、Rhonda M. Lachance、Deborah A. Mischke、Stephen R. Rapp、Rhonda S. Woerndle、Michael D. Ennis

  DOI：10.1021/jm901518t

  日期：2010.3.11

  Polymer-assisted solution-phase (PASP) parallel library synthesis was used to discover a piperazinyl glutamate pyridine as a P2Y(12) antagonist. Exploitation of this lead provided compounds with excellent inhibition of platelet aggregation its measured in a human platelet rich plasma (PRP) assay. Pharmacokinetic and physiochemical properties were optimized through modifications at the 4-position or the pyridine ring and the terminal nitrogen of the piperazine ring, leading to compound (4S)4-[(4-[4-(methoxymethyl)piperdin-1-yl]-6-phenylpyridin-2-yl}carbonyl)amino]-5-oxo-5-4-[(pentyloxy)carbonyl]piperazin-1-yl}pentanoic acid 47s with good human PRP potency, selectivity, in vivo efficacy, and oral bioavallability. Compound 47s was selected for further preclinical evaluations.
• EP2081903B1
  申请人：——

  公开号：EP2081903B1

  公开（公告）日：2014-05-07
• US8093250B2
  申请人：——

  公开号：US8093250B2

  公开（公告）日：2012-01-10
• [EN] 2-AMINOCARBONYL-PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2-AMINOCARBONYL-PYRIDINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2008044217A2

  公开（公告）日：2008-04-17

  [EN] The present invention relates to 2-aminocarbonyl-pyridine derivatives and their use as P2Yi2 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.
  [FR] La présente invention concerne des dérivés de 2-aminocarbonyl-pyridine et leur utilisation en tant qu'antagonistes du récepteur de P2Yi2 dans le traitement et/ou la prévention de maladies ou d'affections vasculaires périphériques, viscéro-vasculaires, hépato-vasculaires et vasculaires rénales, cardiovasculaires et cérébro-vasculaires associées à l'agrégation des plaquettes, y compris la thrombose, chez les humains et d'autres mammifères.